Viatris

Photo
10.01.2023 • News

Viatris Forms Eye Care Unit from Acquisitions

Viatris, formed in November 2020 from the merger of Mylan with Pfizer’s Upjohn division, has established an eye care division following the closure of two acquisitions on Jan. 3.

Photo
17.03.2022 • News

Viatris Selling Biosimilars Unit to Biocon for $3 Billion

Viatris, the new US pharma created in the 2020 merger of Mylan and Pfizer’s Upjohn off-patent franchise, is selling its biosimilars portfolio to Biocon Biologics for up to $3.35 billion. Terms of the deal foresee Biocon paying $2 billion upfront, $1 billion in convertible preferred equity and $335 million in additional payments.

Photo
26.11.2020 • News

Upjohn/Mylan Merger Closes to Form Viatris

Pfizer has completed the spin-off of its Upjohn Business and combined it with Mylan to form Viatris, which began trading on Nov. 17. On closure of the deal, Pfizer stockholders owned about 57% of the outstanding shares of Viatris common stock and Mylan shareholders owned roughly 43%.

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.